MSF's publications are an expression of our belief in the principle of témoignage, or bearing witness, and the belief that we are accountable to those we work for and with. Sharing news about our activities and reflecting on them, offering critiques when necessary, are therefore crucial aspects of our work.

View and download these publications below.

To view the U.S. Annual Reports or International Activity Reports, please visit the Annual Reports page.

Country/Region

August 30, 2017

Yury*, 38, is celebrating a moment he thought would never arrive: he has been cured of extensively drug-resistant tuberculosis (XDR-TB). This moment is also a milestone for Doctors Without Borders/Médecins Sans Frontières (MSF): Yury is the first patient to complete MSF’s tuberculosis treatment program in Belarus, run in close cooperation with the Ministry of Health.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.

August 30, 2017

Yury*, 38, is celebrating a moment he thought would never arrive: he has been cured of extensively drug-resistant tuberculosis (XDR-TB). This moment is also a milestone for Doctors Without Borders/Médecins Sans Frontières (MSF): Yury is the first patient to complete MSF’s tuberculosis treatment program in Belarus, run in close cooperation with the Ministry of Health.

February 14, 2017

NEW YORK/NEW DELHI, FEBRUARY 14, 2017—Five new challenges against flawed patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral (DAA) medicines, including sofosbuvir, daclatasvir and velpatasvir, and increase access for millions of people.